IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Heartland Bank & Trust Co

Heartland Bank & Trust Co decreased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 4.9% during the 1st quarter, HoldingsChannel.com reports. The fund owned 1,482 shares of the medical research company’s stock after selling 76 shares during the period. Heartland Bank & Trust Co’s holdings in IQVIA were worth $343,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of IQV. UMB Bank N A MO acquired a new position in shares of IQVIA during the 4th quarter valued at $26,000. Dividend Assets Capital LLC acquired a new position in shares of IQVIA during the 1st quarter valued at $27,000. Johnson Financial Group Inc. acquired a new position in shares of IQVIA during the 4th quarter valued at $34,000. Catalyst Capital Advisors LLC acquired a new position in shares of IQVIA during the 4th quarter valued at $38,000. Finally, Amplius Wealth Advisors LLC purchased a new stake in IQVIA during the 4th quarter worth $45,000. Institutional investors and hedge funds own 87.12% of the company’s stock.

Shares of NYSE:IQV opened at $201.74 on Thursday. The company has a quick ratio of 0.93, a current ratio of 0.93 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a fifty-two week low of $194.67 and a fifty-two week high of $285.61. The firm has a 50-day simple moving average of $213.11 and a 200 day simple moving average of $233.86. The company has a market cap of $38.19 billion, a PE ratio of 36.35, a P/E/G ratio of 1.42 and a beta of 1.41.

IQVIA (NYSE:IQV – Get Rating) last announced its quarterly earnings data on Wednesday, April 27th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.07. IQVIA had a net margin of 7.69% and a return on equity of 28.80%. The business had revenue of $3.57 billion during the quarter, compared to the consensus estimate of $3.54 billion. During the same quarter in the prior year, the firm earned $2.05 EPS. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, research analysts forecast that IQVIA Holdings Inc. will post 9.48 EPS for the current fiscal year.

Several equities research analysts recently issued reports on IQV shares. Wells Fargo & Company downgraded shares of IQVIA from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $290.00 to $235.00 in a research note on Monday, April 25th. Guggenheim started coverage on shares of IQVIA in a research note on Monday, May 23rd. They set a “buy” rating and a $244.00 price target on the stock. Piper Sandler raised shares of IQVIA from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $231.00 to $255.00 in a research note on Thursday, April 28th. Barclays dropped their price target on shares of IQVIA from $275.00 to $240.00 in a research note on Thursday, April 28th. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Wednesday. Two analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $277.80.

IQVIA Company Profile (Get Rating)

IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Stories